File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fatal lung toxic effects related to dronedarone use

TitleFatal lung toxic effects related to dronedarone use
Authors
Siu, CWWong, MPHo, CMLam, CLDTse, HF
KeywordsAntibiotic agent
Dronedarone
Methylprednisolone
Issue Date2012
PublisherAmerican Medical Association. The Journal's web site is located at http://www.archinternmed.com
Citation
Archives of Internal Medicine, 2012, v. 172 n. 6, p. 516-517 How to Cite?
DOI: http://dx.doi.org/10.1001/archinternmed.2011.1681
AbstractDronedarone is a derivative of amiodarone that aimed to reduce the extracardiac adverse effects while preserving its antiarrhythmic effects for treatment of atrial fibrillation (AF).1 In the ATHENA trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter),2 dronedarone reduced cardiovascular hospitalization and death in patients with nonpermanent atrial fibrillation (AF) with other cardiovascular risk factors. However, an experimental study3 suggested that dronedarone might have toxic effects on the lung greater than or equal to amiodarone. We describe 2 cases of fatal and near-fatal lung toxic effects associated with dronedarone use. Abstract by, American Medical Association.
DescriptionResearch letters
Persistent Identifierhttp://hdl.handle.net/10722/159614
ISSN
0003-9926
2014 Impact Factor: 17.333
ISI Accession Number ID
WOS:000301953800014

 

DC FieldValueLanguage
dc.contributor.authorSiu, CWen_US
dc.contributor.authorWong, MPen_US
dc.contributor.authorHo, CMen_US
dc.contributor.authorLam, CLDen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2012-08-16T05:53:24Z-
dc.date.available2012-08-16T05:53:24Z-
dc.date.issued2012en_US
dc.identifier.citationArchives of Internal Medicine, 2012, v. 172 n. 6, p. 516-517en_US
dc.identifier.issn0003-9926-
dc.identifier.urihttp://hdl.handle.net/10722/159614-
dc.descriptionResearch letters-
dc.description.abstractDronedarone is a derivative of amiodarone that aimed to reduce the extracardiac adverse effects while preserving its antiarrhythmic effects for treatment of atrial fibrillation (AF).1 In the ATHENA trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter),2 dronedarone reduced cardiovascular hospitalization and death in patients with nonpermanent atrial fibrillation (AF) with other cardiovascular risk factors. However, an experimental study3 suggested that dronedarone might have toxic effects on the lung greater than or equal to amiodarone. We describe 2 cases of fatal and near-fatal lung toxic effects associated with dronedarone use. Abstract by, American Medical Association.-
dc.languageengen_US
dc.publisherAmerican Medical Association. The Journal's web site is located at http://www.archinternmed.com-
dc.relation.ispartofArchives of Internal Medicineen_US
dc.subjectAntibiotic agent-
dc.subjectDronedarone-
dc.subjectMethylprednisolone-
dc.subject.meshAged-
dc.subject.meshAmiodarone - adverse effects - analogs and derivatives-
dc.subject.meshFatal Outcome-
dc.subject.meshLung Diseases - chemically induced-
dc.subject.meshMale-
dc.subject.meshAged, 80 and over-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.titleFatal lung toxic effects related to dronedarone useen_US
dc.typeArticleen_US
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hken_US
dc.identifier.emailWong, MP: mwpik@hkucc.hku.hken_US
dc.identifier.emailHo, CM: jhocm@hku.hken_US
dc.identifier.emailLam, CL: dcllam@hku.hken_US
dc.identifier.emailTse, HF: hftse@hku.hken_US
dc.identifier.authoritySiu, CW=rp00534en_US
dc.identifier.authorityWong, MP=rp00348en_US
dc.identifier.authorityHo, CM=rp00258en_US
dc.identifier.authorityLam, CL=rp01345en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1001/archinternmed.2011.1681-
dc.identifier.pmid22450940-
dc.identifier.scopuseid_2-s2.0-84858956030-
dc.identifier.hkuros202200en_US
dc.identifier.hkuros201297-
dc.identifier.volume172en_US
dc.identifier.issue6en_US
dc.identifier.spage516en_US
dc.identifier.epage517en_US
dc.identifier.eissn2168-6114-
dc.identifier.isiWOS:000301953800014-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats